Evonik offers Tessenderlo customers secure supply of glycine
Essen, Germany-based Evonik Industries has assumed ownership of the customer list for the pharmaceutical amino acid glycine of the Tessenderlo Group of Brussels (Belgium). By the end of the year, Tessenderlo will withdraw from the glycine business completely and close its own production plant in Belgium. Evonik’s product line Rexim produces the pharmaceutical amino acid based on the strict specifications of the cGMP (current Good Manufacturing Practice) at its site in Wuming (China), where it is currently expanding capacities.
Through intensive research in the field of white biotechnology, Evonik has continuously expanded its portfolio of pharmaceutical-grade amino acids in recent years. ““Offering Tessenderlo’s customers a sustainable supply of high-quality glycine is one more step in consolidating our pharmaceutical amino acid business,” says Dr. Thomas Hermann, head of the Rexim Product Line, a subsidiary of Evonik’s Health & Nutrition Business Unit.
Other news from the department business & finance
